Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Parabilis Medicines, Inc.PBLS · Entity 3933 | Director | August 22, 2026 | August 25, 2026 |
| TuHURA Biosciences, Inc./NVHURA · Entity 6601 | Director | February 12, 2026 | February 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Parabilis Medicines, Inc.
Report date August 22, 2026 · Filed August 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.36 · Expires 2036-08-21 | Direct | 20,294 |
Reported balance
After 2026-08-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-22 · Grant · Acquired 20,294 · Balance 20,294 F1: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments commencing from August 22, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments commencing from August 22, 2026, subject to the Reporting Person's continued service on each such vesting date.
TuHURA Biosciences, Inc./NV
Report date February 12, 2026 · Filed February 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2036-02-12 | Direct | 156,240 |
Reported balance
After 2026-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-12 · Grant · Acquired 156,240 · Balance 156,240 F1: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2035-03-10 | Direct | 151,883 |
Reported balance
Holding disclosure · report date 2026-02-12 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 151,883 F2: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on March 10, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of March 10, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.
F2: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on March 10, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of March 10, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 22, 2026 Filed Aug 25, 2026 22:14 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | GrantStock Option (Right to Buy) · Derivative | 20,294 | $0.00 Strike: $39.36 | $0.00 |
DisclosureSEC source: 0001193125-26-365484 · ownership.xml · derivative · entry 1 Tendler Craig · CIK 0002061924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,294 Underlying: Common Stock · 20,294 shares Expires 2036-08-21 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments commencing from August 22, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:21 UTC | TuHURA Biosciences, Inc./NV HURA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 156,240 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000897069-26-000369 · form4.xml · derivative · entry 1 Tendler Craig · CIK 0002061924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,240 Underlying: Common Stock · 156,240 shares Expires 2036-02-12 F1 · date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026. F1 · derivative.exercise_date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026. Read SEC document |
| March 10, 2025 Filed Mar 19, 2025 23:13 UTC | TuHURA Biosciences, Inc./NV HURA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 151,883 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000897069-25-000664 · form4.xml · derivative · entry 1 Tendler Craig · CIK 0002061924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,883 Underlying: Common Stock · 151,883 shares Expires 2035-03-10 F1 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of March 10, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.